Table 1.
Endpoint | Pembrolizumab (n = 784) | Placebo (n = 390) | HR (95% CI) | p value |
---|---|---|---|---|
EFS events | 15.7% | 23.8% | 0.63 (0.48-0.82) | .00031 |
EFS at 36 months | 84.5% | 76.8% |
Abbreviations: CI, confidence interval; EFS, event-free survival; HR, hazard ratio; TNBC, triple-negative breast cancer.